Sublingual	sublingual	O	O
absorption	absorption	O	O
of	of	O	O
the	the	O	O
quaternary	quaternary	O	O
ammonium	ammonium	O	O
antiarrhythmic	antiarrhythmic	O	O
agent	agent	O	O
,	,	O	O
UM-272.UM-272	um-272.um-272	O	O
(	(	O	O
N	n	O	O
,	,	O	O
N-dimethylpropranolol	n-dimethylpropranolol	S_chemical	O
)	)	O	O
,	,	O	O
a	a	O	O
quaternary	quaternary	O	O
antiarrhythmic	antiarrhythmic	O	O
agent	agent	O	O
,	,	O	O
was	was	O	O
administered	administered	O	O
sublingually	sublingually	O	O
to	to	O	O
dogs	dogs	O	O
with	with	O	O
ouabain-induced	ouabain-induced	O	O
ventricular	ventricular	O	B_disease
tachycardias	tachycardias	O	I_disease
.	.	O	O

Both	both	O	O
anti-arrhythmic	anti-arrhythmic	O	O
efficacy	efficacy	O	O
and	and	O	O
bioavailability	bioavailability	O	O
were	were	O	O
compared	compared	O	O
to	to	O	O
oral	oral	O	O
drug	drug	O	O
.	.	O	O

Sublingual	sublingual	O	O
UM-272	um-272	O	O
converted	converted	O	O
ventricular	ventricular	O	B_disease
tachycardia	tachycardia	O	S_disease
to	to	O	O
sinus	sinus	O	B_disease
rhythm	rhythm	O	I_disease
in	in	O	O
all	all	O	O
5	5	O	O
dogs	dogs	O	O
.	.	O	O

The	the	O	O
area	area	O	O
under	under	O	O
the	the	O	O
plasma	plasma	O	O
concentration	concentration	O	O
time	time	O	O
curve	curve	O	O
at	at	O	O
90	90	O	O
min	min	O	O
was	was	O	O
4	4	O	O
-	-	O	O
12	12	O	O
times	times	O	O
greater	greater	O	O
than	than	O	O
for	for	O	O
oral	oral	O	O
drug	drug	O	O
,	,	O	O
suggesting	suggesting	O	O
the	the	O	O
existence	existence	O	O
of	of	O	O
an	an	O	O
absorption-limiting	absorption-limiting	O	O
process	process	O	O
in	in	O	O
the	the	O	O
intestine	intestine	O	O
,	,	O	O
and	and	O	O
providing	providing	O	O
an	an	O	O
alternate	alternate	O	O
form	form	O	O
of	of	O	O
administration	administration	O	O
for	for	O	O
quaternary	quaternary	O	O
drugs	drugs	O	O
.	.	O	O

